摘要
目的:评价护心康超微制剂与传统制剂治疗痰瘀阻络型冠心病心绞痛的临床疗效及安全性。方法:采用随机组别、双盲观察、传统饮片平行对照的试验设计方案,共入选60例患者,每组各30例,治疗组用超微护心康片,对照组用传统护心康片,连续用药治疗4周后,观察两组间治疗后的临床疗效及安全性。结果:治疗组与对照组比较,两组间的显效率、心绞痛疗效、硝酸甘油停减率、中医证候疗效有统计学意义(P<0.05),但总有效率、心电图疗效无统计学意义(P>0.05)。结论:护心康片能改善痰瘀阻络型冠心病心绞痛患者的临床症状,且超微护心康片治疗冠心病心绞痛的疗效优于传统护心康片,故超微制剂能广泛地运用于临床。
Objective To observe the clinical curative effects and security of ultro-micro Huxinkang an traditional Huxinkang in treatmerf for patients with coronary heart disease（CHD） of phlegm-stasis blocking collateral type. Methods 60 cases of patients with CHD of phlegm-stasis blocking collateral type were randomly divided into treatment group（ultro-micro Huxinkang） and control group（traditional Huxinkang） with 30 cases each group All clinical data in two groups were compared after treatment for 4 weeks. Results ①The total effectiveness rates were not significantly different between ultro-micro Huxinkang group and traditional Huxinkang group（P 〉 0.05）. But the differences of excellence efficiency, angina pectoris and minus rate of nitroglycerin in the treatment group were all statistically significant （P 〈 0.05）, compared with the control group. ②Between the two groups, the difference of ECG effect was not statistically signifiamt（P〉 0.05）. ③The curative effect of Chinese medicine syndrome of the treatment group was statistically sigaiticmtly diiffient（P〈0.05） from that of the conlml group. Conclusion ①Huxinkang could improve clinical symptoms of patients with CHD of phlegm-stasis blocking collateral type, and the curative effects of ultro-micro Huxinkang on angina pectoris, minus rate of nitroglycerin and the therapeutic effect of Chinese medicine syndrome were all better than those of traditional Huxinkang. ②The results accounted for that the ultro- micro Huxinkang treatment for CHD was better than the traditional Huxinkang. So the ultro-micro preparation can be widely used in clinic .
出处
《深圳中西医结合杂志》
2013年第5期307-310,共4页
Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词
超微制剂
冠心病
护心康
Ultro-micro preparation
Coronary Heart Disease
Huxinkang
Clinical study
